ReviewDrugs & aging2023
Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia - A Narrative Review.
Review in Drugs & aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Endocrinological aspects of sarcopenic obesity.Annals of medicine · 2026Review
- Interplay between sarcopenia and type 2 diabetes: mechanisms, implications, and therapeutic prospects.Nutrition & diabetes · 2026Review
- Development of pharmacological interventions for the treatment of sarcopenia.Annals of translational medicine · 2026Review
- The bidirectional relationship between diabetes and poor muscle function in older adults: data from two population-based studies.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Sarcopenia in Aging: Pathogenesis, Diagnosis, and Emerging Therapeutic Frontiers.Molecular imaging and biology · 2026Review
- An integrated drug repositioning analysis identifies rosiglitazone as a treatment for sarcopenia.Communications biology · 2026Article
- Exploring the protective effect of metformin against sarcopenia: insights from cohort studies and genetics.Journal of translational medicine · 2025Article
- Sarcopenia: the need for early detection, early treatment, and the identification of sensitive measures for predicting treatment response.Asian biomedicine : research, reviews and news · 2025Article
- Perceptions of sarcopenia in patients, health and care professionals, and the public: a scoping review of studies from different countries.European geriatric medicine · 2025Article
- Cross-sectional and longitudinal associations between glycaemic measures and grip strength in people without diabetes in the UK Biobank cohort study.European geriatric medicine · 2025Article
- Mitochondrial dysfunction in age-related sarcopenia: mechanistic insights, diagnostic advances, and therapeutic prospects.Frontiers in cell and developmental biology · 2025Review
- Fedratinib reveals chemotherapeutic potential in esophageal squamous cell cancer.Frontiers in pharmacology · 2025Article
- Effects of Hypoglycemic Agents on The Musculoskeletal System: A Comprehensive Review.Drug design, development and therapy · 2025Review
- Drug risks associated with sarcopenia: a real-world and GWAS study.BMC pharmacology & toxicology · 2024Article
- Emerging Therapeutic Strategies in Sarcopenia: An Updated Review on Pathogenesis and Treatment Advances.International journal of molecular sciences · 2024Review
- The Current Landscape of Pharmacotherapies for Sarcopenia.Drugs & aging · 2024Article
- Drug-related sarcopenia as a secondary sarcopenia.Geriatrics & gerontology international · 2024Review
- Diabetes Pharmacotherapy and its effects on the Skeletal Muscle Energy Metabolism.Mini reviews in medicinal chemistry · 2024Review
- Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age.Nutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, the age-related loss of muscle strength and mass or quality, is a common condition with major adverse consequences. Although the pathophysiology is incompletely understood, there are common mechanisms between sarcopenia and the phenomenon of accelerated ageing seen in diabetes mellitus. Drugs currently used to treat type 2 diabetes mellitus may have mechanisms of action that are relevant to the prevention and treatment of sarcopenia, for those with type 2 diabetes and those without diabetes. This review summarises shared pathophysiology between sarcopenia and diabetes mellitus, including the effects of advanced glycation end products, mitochondrial dysfunction, chronic inflammation and changes to the insulin signalling pathway. Cellular and animal models have generated intriguing, albeit mixed, evidence that supports possible beneficial effects on skeletal muscle function for some classes of drugs used to treat diabetes, including metformin and SGLT2 inhibitors. Most human observational and intervention evidence for the effects of these drugs has been derived from populations with type 2 diabetes mellitus, and there is a need for intervention studies for older people with, and at risk of, sarcopenia to further investigate the balance of benefit and risk in these target populations. Not all diabetes treatments will be safe to use in those without diabetes because of variable side effects across classes. However, some agents [including glucagon-like peptide (GLP)-1 receptor agonists and SGLT2 inhibitors] have already demonstrated benefits in populations without diabetes, and it is these agents, along with metformin, that hold out the most promise for further investigation in sarcopenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.